Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).

Trial Details

NCT ID
NCT06846463
Phase
PHASE2
Sponsor
Virginia Commonwealth University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Zanubrutinib
Locations (sample)
  • Richmond, Virginia, United States|37.55376,-77.46026

Key Eligibility Criteria

  • Patients must have a documented pathologic diagnosis of DLBCL at any stage.
  • Must have documented MYD88 L265P, CD79B, or NOTCH1 truncation mutation or be CD5+ by IHC.
  • Age ≥18 years on the day of signing the informed consent form.
  • Patients must have measurable disease on Positron Emission Tomography-Computed Tomography scan (CT/PET) imaging.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →